Literature DB >> 16449284

The effect of single and repeatedly high concentrations of C-reactive protein on cardiovascular and non-cardiovascular mortality in patients starting with dialysis.

Wendy P J den Elzen1, Jeannette G van Manen, Elisabeth W Boeschoten, Raymond T Krediet, Friedo W Dekker.   

Abstract

BACKGROUND: Single measurements of C-reactive protein (CRP) predict cardiovascular mortality in dialysis patients. However, CRP can be temporarily elevated due to infections. Therefore, we investigated the effect of single and repeatedly high concentrations of CRP on cardiovascular and non-cardiovascular mortality in incident dialysis patients.
METHODS: In the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD), patients starting with dialysis were enrolled between 1997 and 2002. From 635 patients, plasma CRP concentrations were determined at 3 and 6 months of follow-up. Concentrations >10 mg/l were regarded as 'high'. Patients were followed until time of death, or censored at the end of follow-up (1 May 2004). Cox regression models were performed to compare mortality between patients with repeatedly low CRP, with varying CRP and with repeatedly high CRP.
RESULTS: At the end of follow-up, 247 patients had died, of which 107 patients died of cardiovascular disease (47.8%). Patients with low CRP(3 months) and high CRP(6 months) were at increased cardiovascular [adjusted hazard ratio (HR): 2.59, 95% CI: 1.25-5.37] and non-cardiovascular (adjusted HR: 2.18, 95% CI: 1.11-4.28) mortality risk compared with patients with low CRP on both occasions. Moreover, patients with high CRP on both occasions had a higher cardiovascular (adjusted HR: 1.51, 95% CI: 0.72-3.18) and non-cardiovascular (adjusted HR: 2.25, 95% CI: 0.96-5.28) mortality risk than patients with high CRP(3 months) and low CRP(6 months).
CONCLUSIONS: Single and repeatedly high concentrations of CRP (>10 mg/l) are related to both cardiovascular and non-cardiovascular mortality in dialysis patients. A high CRP concentration, therefore, has implications for the treatment of cardiovascular as well as non-cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16449284     DOI: 10.1093/ndt/gfk092

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  14 in total

1.  C-reactive protein variability is associated with vascular access outcome in hemodialysis patients.

Authors:  Wei-Hung Kuo; Yueh-Ting Lee; Hwee-Yeong Ng; Chun-Yeh Wang; Chien-Hsing Wu; Chien-Te Lee
Journal:  J Clin Lab Anal       Date:  2017-04-27       Impact factor: 2.352

Review 2.  Monitoring of inflammation in patients on dialysis: forewarned is forearmed.

Authors:  Christiaan L Meuwese; Peter Stenvinkel; Friedo W Dekker; Juan J Carrero
Journal:  Nat Rev Nephrol       Date:  2011-03       Impact factor: 28.314

3.  Coagulation factors as biological risk markers of endothelial dysfunction. Association with the thrombotic episodes of chronic hemodialysis patients.

Authors:  A Sioulis; P Malindretos; A Makedou; P Makris; D Grekas
Journal:  Hippokratia       Date:  2009-10       Impact factor: 0.471

4.  Effect of different dialysis modalities on microinflammatory status and endothelial damage.

Authors:  Ana Merino; José Portolés; Rafael Selgas; Raquel Ojeda; Paula Buendia; Javier Ocaña; M Auxiliadora Bajo; Gloria del Peso; Julia Carracedo; Rafael Ramírez; Alejandro Martín-Malo; Pedro Aljama
Journal:  Clin J Am Soc Nephrol       Date:  2010-01-07       Impact factor: 8.237

5.  CCR5 deletion protects against inflammation-associated mortality in dialysis patients.

Authors:  Friso L H Muntinghe; Marion Verduijn; Mike W Zuurman; Diana C Grootendorst; Juan Jesus Carrero; Abdul Rashid Qureshi; Karin Luttropp; Louise Nordfors; Bengt Lindholm; Vincent Brandenburg; Martin Schalling; Peter Stenvinkel; Elisabeth W Boeschoten; Raymond T Krediet; Gerjan Navis; Friedo W Dekker
Journal:  J Am Soc Nephrol       Date:  2009-04-23       Impact factor: 10.121

6.  Effect of Epoetin alfa dose changes on hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below 11 g/dL.

Authors:  Brian D Bradbury; Mark D Danese; Michelle Gleeson; Cathy W Critchlow
Journal:  Clin J Am Soc Nephrol       Date:  2009-03-04       Impact factor: 8.237

Review 7.  Noncardiovascular mortality in CKD: an epidemiological perspective.

Authors:  Dinanda J de Jager; Marc G Vervloet; Friedo W Dekker
Journal:  Nat Rev Nephrol       Date:  2014-02-04       Impact factor: 28.314

8.  Association between Inflammation and Cardiac Geometry in Chronic Kidney Disease: Findings from the CRIC Study.

Authors:  Jayanta Gupta; Elizabeth A Dominic; Jeffrey C Fink; Akinlolu O Ojo; Ian R Barrows; Muredach P Reilly; Raymond R Townsend; Marshall M Joffe; Sylvia E Rosas; Melanie Wolman; Samir S Patel; Martin G Keane; Harold I Feldman; John W Kusek; Dominic S Raj
Journal:  PLoS One       Date:  2015-04-24       Impact factor: 3.240

9.  Increasing high-sensitive C-reactive protein level predicts peritonitis risk in chronic peritoneal dialysis patients.

Authors:  Yu-Jen Su; Shang-Chih Liao; Ben-Chung Cheng; Jyh-Chang Hwang; Jin-Bor Chen
Journal:  BMC Nephrol       Date:  2013-09-04       Impact factor: 2.388

10.  Three-month variation of plasma pentraxin 3 compared with C-reactive protein, albumin and homocysteine levels in haemodialysis patients.

Authors:  Bodil Sjöberg; Sunna Snaedal; Peter Stenvinkel; Abdul Rashid Qureshi; Olof Heimbürger; Peter Bárány
Journal:  Clin Kidney J       Date:  2014-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.